The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Abstract
The combination of CDK4/6 inhibitors with antiestrogen therapies significantly improves clinical outcomes in ER-positive advanced breast cancer. To identify mechanisms of acquired resistance, we analyzed serial biopsies and rapid autopsies from patients treated with the combination of the CDK4/6 inhibitor ribociclib with letrozole. This study revealed that some resistant tumors acquired RB loss, whereas other tumors lost PTEN expression at the time of progression. In breast cancer cells, ablation of PTEN, through increased AKT activation, was sufficient to promote resistance to CDK4/6 inhibition in vitro and in vivo. Mechanistically, PTEN loss resulted in exclusion of p27 from the nucleus, leading to increased activation of both CDK4 and CDK2. Because PTEN loss also causes resistance to PI3Kα inhibitors, currently approved in the post-CDK4/6 setting, these findings provide critical insight into how this single genetic event may cause clinical cross-resistance to multiple targeted therapies in the same patient, with implications for optimal treatment-sequencing strategies. Significance: Our analysis of serial biopsies uncovered RB and PTEN loss as mechanisms of acquired resistance to CDK4/6 inhibitors, utilized as first-line treatment for ER-positive advanced breast cancer. Importantly, these findings have near-term clinical relevance because PTEN loss also limits the efficacy of PI3Kα inhibitors currently approved in the post-CDK4/6 setting. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“Although CDK4/6 inhibitors are commonly used in patients with advanced ER-positive breast cancer, the PI3Kα-selective inhibitor alpelisib was only recently approved as a second line of treatment for PIK3CAmutated ER-positive breast cancer (21).”
BackgroundSelf-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., et al. (2002) · Nature Medicine · doi:10.1038/nm762 · Cited by 701
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationParaiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 551
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504 · cited 1×
“Previous preclinical studies have shown that PTEN loss also affects the activity of BRAF (30), EGFR (31), and immune checkpoint inhibitors (32) in other settings, suggesting that PTEN loss may emerge as a resistance mechanism in many therapeutic paradigms.”
BackgroundTurner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Self-citationAberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09068-2 · Cited by 408
Self-citationCondorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Self-citationRb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Tan, H.-L., Sood, A., Rahimi, H. A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C. D., Epstein, J. I., Netto, G. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1982 · Cited by 346
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
Phosphorylation of p27 Kip1 Regulates Assembly and Activation of Cyclin D1-Cdk4
Larrea, M. D., Liang, J., Silva, T. D., Hong, F., Shao, S. H., Han, K. C.-Z., Dumont, D. J., & Slingerland, J. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02300-07 · Cited by 113
PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells.
Zhu, X., Kwon, C. H., Schlosshauer, P. W., Ellenson, L. H., & Baker, S. J. (2001) · PubMed · Cited by 81
Mullany, L. K., Nelsen, C. J., Hanse, E. A., Goggin, M. M., Anttila, C. K., Peterson, M., Bitterman, P. B., Raghavan, A., Crary, G. S., & Albrecht, J. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702110200 · Cited by 59
Juric, D., Münster, P. N., Campone, M., Ismail-Khan, R. R., García‐Estévez, L., Hamilton, E. P., Becerra, C. R., Boer, R. H. D., Hui, R., Gonçalvès, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.568 · Cited by 33
Self-citationCaldon, C. E., Sergio, C. M., Sutherland, R. L., & Musgrove, E. A. (2013) · Cell Cycle · doi:10.4161/cc.23409 · Cited by 27
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Predicting drug response and synergy using a deep learning model of human cancer cells
Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., Ma, J., & Ideker, T. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.014 · Cited by 544
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Spring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 468
Self-citation
Metadata
- Authors
- Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T., Healy, C., Peterson, R., Yanase, S., Jakubik, C. T., Henderson, L. E., Damon, L. J., Timonina, D., Sanidas, I., Pinto, C. J., Mino-Kenudson, M., Stone, J. R., Dyson, N. J., Ellisen, L. W., Bardia, A., Ebi, H., Benes, C. H., Engelman, J. A., & Juric, D.
- Venue
- Cancer Discovery
- Published
- 2020-01-01
- Volume
- 10
- Issue
- 1
- Pages
- 72-85
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2980008739
- Cited by
- 270
- References
- 33
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.